Hot Pursuit     13-May-22
Alembic Pharmaceuticals Ltd gains for third straight session
Alembic Pharmaceuticals Ltd is quoting at Rs 742, up 1.98% on the day as on 12:49 IST on the NSE. The stock is down 20.98% in last one year as compared to a 9.14% jump in NIFTY and a 8.48% jump in the Nifty Pharma index.

Alembic Pharmaceuticals Ltd gained for a third straight session today. The stock is quoting at Rs 742, up 1.98% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 1.34% on the day, quoting at 16019.3. The Sensex is at 53598.52, up 1.26%. Alembic Pharmaceuticals Ltd has slipped around 4.28% in last one month.

Meanwhile, Nifty Pharma index of which Alembic Pharmaceuticals Ltd is a constituent, has slipped around 7.35% in last one month and is currently quoting at 12424.45, up 2.29% on the day. The volume in the stock stood at 2.55 lakh shares today, compared to the daily average of 3.01 lakh shares in last one month.

The benchmark May futures contract for the stock is quoting at Rs 749, up 2.93% on the day. Alembic Pharmaceuticals Ltd is down 20.98% in last one year as compared to a 9.14% jump in NIFTY and a 8.48% jump in the Nifty Pharma index.

The PE of the stock is 18.01 based on TTM earnings ending March 22.

Previous News
  Alembic Pharm gets US FDA approvals for five products in Q1 FY24
 ( Hot Pursuit - 03-Jul-23   09:54 )
  Alembic Pharmaceuticals receives USFDA approval for various products
 ( Corporate News - 09-May-24   09:01 )
  Alembic Pharma's Panelav unit successfully completes USFDA inspection
 ( Corporate News - 26-Jul-24   13:36 )
  Alembic Pharma karkhadi facility gets two USFDA observations
 ( Hot Pursuit - 25-Mar-23   12:35 )
  Alembic Pharma rises after receiving USFDA nod for cancer drug
 ( Hot Pursuit - 04-Jul-24   13:00 )
  Volumes soar at Lemon Tree Hotels Ltd counter
 ( Hot Pursuit - 02-Jan-24   11:00 )
  Alembic Pharmaceuticals consolidated net profit rises 596.17% in the March 2023 quarter
 ( Results - Announcements 05-May-23   17:32 )
  Alembic Pharmaceuticals receives multiple product approvals from USFDA
 ( Corporate News - 03-Jul-23   09:11 )
  Alembic receives USFDA approval for Fulvestrant Injection
 ( Corporate News - 26-Dec-22   09:10 )
  Alembic Pharmaceuticals consolidated net profit declines 18.68% in the September 2022 quarter
 ( Results - Announcements 11-Nov-22   14:55 )
  Alembic Pharma records 48% growth in Q3 PAT
 ( Hot Pursuit - 05-Feb-24   16:29 )
Other Stories
  Voltamp Transformers hits record high after strong Q1 result
  29-Jul-24   16:53
  Arvind slides as PAT tumble 40% YoY in Q1 FY25
  29-Jul-24   16:40
  Vedant Fashions slides after Q1 PAT drops to Rs 1,067 cr
  29-Jul-24   15:38
  Adani Total Gas gains after Q1 PAT jumps 20% YoY to Rs 177 cr in FY25
  29-Jul-24   15:08
  Spandana Sphoorty Financial Ltd leads losers in 'A' group
  29-Jul-24   15:00
  Strides Pharma hits 52-week high on reporting turnaround Q1 performance
  29-Jul-24   14:51
  Antony Waste Handling Cell Ltd leads losers in 'B' group
  29-Jul-24   14:45
  Volumes spurt at FDC Ltd counter
  29-Jul-24   14:30
  Consumer Durables shares fall
  29-Jul-24   14:00
  FMCG stocks edge lower
  29-Jul-24   14:00
Back Top